NCT07132333

Brief Summary

Molecular Inflammation Board at the Center for Personalized Medicine

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,000

participants targeted

Target at P75+ for all trials

Timeline
79mo left

Started Nov 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress35%
Nov 2022Nov 2032

Study Start

First participant enrolled

November 16, 2022

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

August 11, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 20, 2025

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2032

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2032

Last Updated

August 20, 2025

Status Verified

August 1, 2025

Enrollment Period

10 years

First QC Date

August 11, 2025

Last Update Submit

August 19, 2025

Conditions

Psoriasis (PsO)Psoriasis ArthritisInflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)Spondylarthropathies

Keywords

chronic inflammatory diseasespersonalized medicine

Outcome Measures

Primary Outcomes (1)

  • Therapy persistence

    Duration of intervention with biological agent

    Through study completion, an average of 1 year

Interventions

Biologic AgentBIOLOGICAL

Intervention with biologic agents

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with chronic inflammatory diseases and indication for therapy with biologic agents

You may qualify if:

  • Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
  • Given informed consent
  • years of age

You may not qualify if:

  • No capacity to consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Tübingen - Center for Personalized Medicine

Tübingen, 72076, Germany

RECRUITING

MeSH Terms

Conditions

PsoriasisInflammatory Bowel DiseasesColitis, UlcerativeSpondylarthropathies

Interventions

Biological Factors

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal DiseasesColitisColonic DiseasesSpondylarthritisSpondylitisSpinal DiseasesBone DiseasesMusculoskeletal DiseasesArthritisJoint Diseases

Central Study Contacts

Nisar P Malek, Prof. Dr.

CONTACT

+4970712982722zpm-meb@med.uni-tuebingen.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
14 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 11, 2025

First Posted

August 20, 2025

Study Start

November 16, 2022

Primary Completion (Estimated)

November 1, 2032

Study Completion (Estimated)

November 1, 2032

Last Updated

August 20, 2025

Record last verified: 2025-08

Locations

DE(1)